Retatrutide

Overview

Retatrutide is a triple agonist peptide acting simultaneously at GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. It represents the next generation of incretin-based metabolic research compounds beyond dual GLP-1/GIP agonists.

Research Context

Phase 2 clinical data for Retatrutide published in 2023 documented weight reductions of up to 24% over 48 weeks — outcomes exceeding those observed with semaglutide or tirzepatide in comparable timeframes. The triple receptor mechanism differentiates it from dual agonists: GLP-1 and GIP activity address insulin secretion and satiety, while glucagon receptor engagement drives additional energy expenditure and lipolysis. Research interest spans obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH), and cardiometabolic risk reduction. It is currently in Phase 3 investigation. The compound represents the most advanced metabolic peptide in the Biohacker catalogue in terms of recent clinical data.

Oral Capsule Format

Retatrutide’s incretin-class peptide structure requires robust protection from gastric acid to reach the small intestine intact. Biohacker’s enteric capsule system and permeation-enhancer matrix address both the acid-stability challenge and the epithelial absorption barrier.

2mg per capsule  ·  60 capsules per bottle. Every batch independently tested for purity, mass confirmation, and endotoxin compliance. Certificate of Analysis available for each lot.

For research purposes only. Not for human or veterinary use.